AMA004 is a gene therapy product for the treatment of patients with the dry form of age related macular degeneration (AMD). AMD is the main cause of irreversible impaired vision and blindness in elderly living in industrialized countries. The dry form of the disease is characterized by inflammation and destruction of the macula. The wet form is a later stage of the disease characterized by choroidal neovascularization (CNV) resulting from the growth of abnormal leaky blood vessels from the choroid into the retina. Using AMA004 we intend to stop the macular degeneration in patients by administration of an SVec vector encoding an anti-inflammatory protein.